THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 27 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $482,000 | -2.6% | 500,000 | 0.0% | 0.87% | +22.5% |
| Q1 2020 | $495,000 | -4.3% | 500,000 | 0.0% | 0.71% | -11.8% |
| Q4 2019 | $517,000 | +11.2% | 500,000 | 0.0% | 0.81% | +12.7% |
| Q3 2019 | $465,000 | +7.6% | 500,000 | 0.0% | 0.72% | +13.3% |
| Q2 2019 | $432,000 | -12.6% | 500,000 | 0.0% | 0.63% | -60.8% |
| Q1 2019 | $494,000 | -3.9% | 500,000 | 0.0% | 1.61% | -24.0% |
| Q4 2018 | $514,000 | -12.7% | 500,000 | 0.0% | 2.12% | +3.5% |
| Q3 2018 | $589,000 | +19.0% | 500,000 | 0.0% | 2.05% | +12.6% |
| Q2 2018 | $495,000 | -1.0% | 500,000 | 0.0% | 1.82% | -13.3% |
| Q1 2018 | $500,000 | -8.4% | 500,000 | 0.0% | 2.10% | -2.7% |
| Q4 2017 | $546,000 | -56.3% | 500,000 | -50.0% | 2.16% | -10.1% |
| Q3 2017 | $1,250,000 | -7.3% | 1,000,000 | 0.0% | 2.40% | +2.3% |
| Q2 2017 | $1,349,000 | +7.0% | 1,000,000 | 0.0% | 2.35% | +22.0% |
| Q1 2017 | $1,261,000 | +10.9% | 1,000,000 | 0.0% | 1.92% | +35.8% |
| Q4 2016 | $1,137,000 | – | 1,000,000 | – | 1.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| LINDEN ADVISORS LP | 71,957,000 | $88,374,000 | 3.14% |
| Context Capital Management, LLC | 3,500,000 | $4,288,000 | 2.87% |
| Mohican Financial Management, LLC | 1,000,000 | $1,250,000 | 2.40% |
| Verition Fund Management LLC | 8,000,000 | $9,835,000 | 0.79% |
| ZAZOVE ASSOCIATES LLC | 8,170,000 | $10,024,000 | 0.51% |
| Baupost Group | 30,000,000 | $37,125,000 | 0.46% |
| WOLVERINE ASSET MANAGEMENT LLC | 24,020,000 | $29,431,000 | 0.33% |
| SSI INVESTMENT MANAGEMENT LLC | 3,007,000 | $3,683,000 | 0.31% |
| CSS LLC/IL | 2,900,000 | $3,556,000 | 0.17% |
| Rock Springs Capital Management LP | 1,500,000 | $1,844,000 | 0.08% |